Company profile
Kyowa Kirin Co., Ltd.
Pipeline5 assets
- ziftomenibKOMZIFTI / Menin / Small Molecule / OncologyAcute Myeloid Leukemia (AML) (Combination)Phase 3ActiveGlobalRelapsed or refractory (R/R) NPM1-mutant AMLPre-RegistrationNDA Submitted / Priority ReviewUS
- rocatinlimabKHK4083 / AMG 451 / OX40 / Monoclonal Antibody / Immunology/AllergyModerate to Severe Atopic DermatitisPhase 3ActiveGlobalUSEUJPPrurigo NodularisPhase 3ActiveGlobalAsthmaPhase 2ActiveGlobal
- atidarsagene autotemcelOTL-200 / Lenmeldy / Libmeldy / ARSA / Hematopoietic Stem Cell (HSC) Gene Therapy / Rare DiseasesEarly-onset Metachromatic Leukodystrophy (MLD)Pre-RegistrationPreparation underway for clinical trial / Regulatory ReviewJP
- tivozanibKHK4951 / VEGF Receptor Tyrosine Kinase / Small Molecule / OphthalmicOphthalmic DiseasesPhase 2/3ActiveGlobal
- mogamulizumabKW-0761 / POTELIGEO / CCR4 / Monoclonal Antibody / OncologyMycosis fungoides and Sézary syndromePre-RegistrationFiledCanada
Latest news16 items
All newsKyowa Kirin Highlights Upcoming Presentation of Phase 3 PROPEL 3 Results for Oral Infigratinib in Achondroplasia at ICCBH 2026
Presentation / Abstract • Phase 3ICCBH 2026 presentation Wed, Jun 24, 2026